Drug intelligence / Profile preview

timepidium bromide

Development stage: Unknown
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

Timepidium bromide is a quaternary ammonium antimuscarinic (anticholinergic) agent used for the symptomatic treatment of visceral spasms and pain associated with various gastrointestinal disorders. It acts as a muscarinic receptor antagonist and does not cross the blood-brain barrier due to its quaternary nitrogen structure, resulting in peripheral action without central side effects. The drug was originally introduced by Tanabe Seiyaku in Japan under the brand name Sesden.

Brand names: SesdenTIMEPIDIUM BROMIDE Tablets 30mg "SAWAI"
Other names: timepidiumbromuro de timepidiobromure de timepidiumtimepidii bromidum5-methoxy-3-(1-methylpiperidylidene)di-(2-thienyl)methane methobromide

Targets

CHRM5 (M5)CHRM2 (M2)CHRM4 (M4)CHRM3 (M3)M1 (Muscarinic acetylcholine receptor M1)

Beyond the preview

Go deeper on timepidium bromide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on timepidium bromide.

Explore the full profile